Erratum: Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

Authors

  • Paul Emery,

  • Roy M. Fleischmann,

  • Larry W. Moreland,

  • Elizabeth C. Hsia,

  • Ingrid Strusberg,

  • Patrick Durez,

  • Peter Nash,

  • Eric Jason B. Amante,

  • Melvin Churchill,

  • Won Park,

  • Bernardo Antonio Pons-Estel,

  • Mittie K. Doyle,

  • Sudha Visvanathan,

  • Weichun Xu,

  • Mahboob U. Rahman

Errata

This article corrects:

  1. Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis Volume 60, Issue 8, 2272–2283, Article first published online: 30 July 2009

No abstract is available for this article.

Ancillary